Cortisone

Cortisone

SCHEMBL4502

CC(=O)O.C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Cortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 10/20 0.94
NR3C1 P04150 5/20 0.94
SERPINA6 P08185 4/20 0.94
TSHR P16473 3/20 0.94
LMNA P02545 3/20 0.94
SHBG P04278 3/20 0.94
CYP3A4 P08684 3/20 0.94
SMN1; SMN2 Q16637 3/20 0.94
PMP22 Q01453 2/20 0.94
ALDH1A1 P00352 2/20 0.94
CYP2D6 P10635 1/20 0.94
KCNA1 Q09470 1/20 0.94
SLC47A1 Q96FL8 1/20 0.94
FNTA P49354 5/20 0.77
FNTB P49356 5/20 0.77
KMT2A Q03164 3/20 0.77
BLM P54132 2/20 0.77
MEN1 O00255 2/20 0.77
AR P10275 1/20 0.77
HIF1A Q16665 5/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cortisone SCHEMBL10089738 0.97 HSD17B10 (1.00) HSD17B10NR3C1SERPINA6TSHRLMNA
Cortisone SCHEMBL4888 0.97 HSD17B10 (1.00) HSD17B10NR3C1SERPINA6TSHRLMNA
Cortisone SCHEMBL13026135 0.97 HSD17B10 (1.00) HSD17B10NR3C1SERPINA6TSHRLMNA
Cortisone SCHEMBL6535496 0.97 HSD17B10 (1.00) HSD17B10NR3C1SERPINA6TSHRLMNA
Cortisone SCHEMBL9926754 0.97 HSD17B10 (1.00) HSD17B10NR3C1SERPINA6TSHRLMNA
Cortisone SCHEMBL13332835 0.97 HSD17B10 (1.00) HSD17B10NR3C1SERPINA6TSHRLMNA
Cortisone SCHEMBL5082082 0.96 HSD17B10 (0.98) HSD17B10NR3C1SERPINA6TSHRLMNA
Cortisone SCHEMBL5082086 0.96 HSD17B10 (0.98) HSD17B10NR3C1SERPINA6TSHRLMNA
Cortisone SCHEMBL28537808 0.96 HSD17B10 (0.98) HSD17B10NR3C1SERPINA6TSHRLMNA
Cortisone SCHEMBL28542114 0.96 HSD17B10 (0.98) HSD17B10NR3C1SERPINA6TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 16703 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745155-A1 POWDER CONTAINING PARTICLES OF GELATIN DERIVATIVE AND APPLICATION OF SAME IN MEDICAL TREATMENT National Institute for Materials Science (JP) 2026-05-20 EP claimed
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
EP-3125943-B1 PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES MERCK SHARP & DOHME LLC (US) 2026-04-22 EP claimed
EP-4724049-A1 MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF Catalent Ontario Limited (CA) 2026-04-15 EP claimed
US-20260091052-A1 MICRORNA AND USES THEREOF IN PREVENTION AND/OR TREATMENT OF FIBROPLASIA MEDICAL SIGN AND/OR SYNDROME BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) 2026-04-02 US claimed
US-12528874-B2 Methods and compositions for treating systemic lupus erythematosus (SLE) with mosunetuzumab GENENTECH, INC. (US) 2026-01-20 US claimed
EP-4615513-A1 BISECTING-GLYCAN BRIDGED CONJUGATION FOR PRODUCING GLYCOPROTEIN CONJUGATES Merck Sharp & Dohme LLC (US) 2025-09-17 EP claimed
EP-3829569-B1 SPINOSYN FORMULATIONS FOR USE IN THE TREATMENT OF DEMODEX-INDUCED OCULAR CONDITIONS APERTA BIOSCIENCES LLC (US) 2025-09-03 EP claimed
EP-4580674-A2 ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) Flagship Pioneering Innovations VI, LLC (US) 2025-07-09 EP claimed
CN-120154586-A Powder aerosol composition for inhalation, powder aerosol for inhalation, preparation method of powder aerosol for inhalation and powder aerosol for inhalation 上海臣邦医药科技股份有限公司 2025-06-17 CN claimed
EP-0343268-A1 Pharmaceutical composition and process for preparing the same BIOGAL GYOGYSZERGYAR (HU) 1989-11-29 EP claimed
US-4867985-A CONTROLLED RELEASE OF NON-STEROID ANTIINFLAMMATORY AGENTS EUROCELTIQUE S.A. (LU) 1989-09-19 US claimed
EP-0209403-A2 Process for preparing ultrafine particles of organic compounds Research Development Corporation of Japan (JP) 1987-01-21 EP claimed
US-4563351-A SUSTAINED RELEASE FORSYTH DENTAL INFIRMARY FOR CHILDREN (US) 1986-01-07 US claimed
US-4540602-A Process for the preparation of activated pharmaceutical compositions FREUND INDUSTRY COMPANY, LIMITED (JP) 1985-09-10 US claimed
EP-0147780-A2 Drug delivery device MERCK & CO. INC. (US) 1985-07-10 EP claimed
EP-0129893-A2 Ground mixture Takeda Chemical Industries, Ltd. (JP) 1985-01-02 EP claimed
US-4317816-A TREATMENT WITH GLUCOCORTICOID AND SAPOININ OF GINSENG OSAKA CHEMICAL LABORATORY CO., LTD. (JP) 1982-03-02 US claimed
US-3962430-A Sterilization of solid non-electrolyte medicinal agents employing sodium chloride MERCK & CO., INC. (US) 1976-06-08 US claimed
US-3960757-A HYDROPHOBIC TOYO JOZO CO., LTD. (JA) 1976-06-01 US claimed